Targeting SOST using a small-molecule compound retards breast cancer bone metastasis.

ABSTRACT:

Background

Breast cancer metastasis to the bone can be exacerbated by osteoporosis, is associated with poor long-term survival, and has limited therapeutic options. Sclerostin (SOST) is an endogenous inhibitor of bone formation, and an attractive target for treatment of osteoporosis. However, it is unclear whether SOST can be used as a therapeutic target for bone metastases of breast cancer, and whether small molecule compounds that target SOST in breast cancer cells can inhibit breast cancer bone metastasis.

Methods

SOST expression in 442 breast cancer tissues was characterized by immunohistochemistry and statistically analyzed for the association with breast cancer bone metastases. Bone metastatic breast cancer SCP2 cells were induced for SOST silencing or overexpression a

SUBMITTER: Sun L 

PROVIDER: S-EPMC9798707 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature